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Abstract: Whilst the survival rates of childhood acute lymphoblastic leukemia (ALL) have increased 
remarkably over the last decades, the therapy resistance and toxicity are still the major causes 
of treatment failure. It was shown that overexpression of heme oxygenase-1 (HO-1) promotes 
proliferation and chemoresistance of cancer cells. In humans, the HO-1 gene (HMOX1) expression is 
modulated by two polymorphisms in the promoter region: (GT)n-length polymorphism and single­
nucleotide polymorphism (SNP) A(-413)T, with short GT repeat sequences and 413-A variants linked 
to an increased HO-1 inducibility. We found that the short alleles are significantly more frequent in 
ALL patients in comparison to the control group, and that their presence may be associated with a 
higher risk of treatment failure, reflecting the role of HO-1 in chemoresistance. We also observed 
that the presence of short alleles may predispose to develop chemotherapy-induced neutropenia. In 
case of SNP, the 413-T variant co-segregated with short or long alleles, while 413-A almost selectively 
co-segregated with long alleles, hence it is not possible to determine if SNPs are actually of phenotypic 
significance. Our results suggest that HO-1 can be a potential target to overcome the treatment failure 
in ALL patients.
Keywords: pediatric acute lymphoblastic leukemia; heme oxygenase-1; chemotherapy induced 
neutropenia; minimal residual disease
1. Introduction
Acute lymphoblastic leukemia (ALL) is one of the most common hematological neo­
plasms that affects the entire lifespan of both infants and adults, with significant prevalence 
between the ages of 2 and 6 years. Among children, more than 80% cases of ALL are
B-cell precursor ALL (BCP-ALL) [1]. Prognosis and outcome in ALL depend on several fac­
tors including: age, genetic aberrations and gene expression profile, prednisone response, 
leukemia characteristics and last but not least— an initial leukemic cells responsiveness to 
the induction therapy, defined as minimal residual disease (MRD), that is the strongest 
independent risk factor for relapse in childhood ALL [1- 3]. Since MRD is a measurement 
of drug resistance in vivo and reflects multiple cellular, host, and treatment variables, it
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has been therefore used for refining initial treatment stratification to the risk categories 
(standard (SR), intermediate (IR), and high risk (HR)), allowing to tailor the intensity of 
chemotherapy for the individual patient [4] . Although survival rates of childhood BCP- 
ALL have increased remarkably, reaching up to 90% in developed countries [5,6], therapy 
resistance and toxicity are still the m ost important barriers to survival, associated with 
high morbidity and mortality [7- 10]. Among them, neutropenia (chemotherapy-induced 
neutropenia— CIN) [11] results in a high risk of life-threatening infections and therefore 
is the primary cause of dose reductions and dose delays during chemotherapy [12]. For 
the treatment and prophylaxis of CIN, human recombinant G-CSF (granulocyte colony 
stimulating factor) is recommended [13,14]. To guide more efficient and cost-effective 
applications of the G-CSF, a number of studies have attempted to define the precise risk 
factors for CIN [15]. Although the frequency of CIN is related to some non-genetic vari­
ables, including chemotherapy scheme, cancer type and such patient-specific factors as age, 
presence of concomitant diseases and general health status [16,17], little is known about the 
genetic factors affecting susceptibility to chemotherapy-induced myelosuppression [18,19].
Some chemotherapeutic agents that m ight be used for ALL treatment (such as dox­
orubicin, vinblastine or camptothecin) [20] increase the level of oxidative stress, as their 
antitumor activity depends directly on H2O2-induced apoptosis [21- 25]. One of the crit­
ical cytoprotective proteins induced in response to oxidative stress is heme oxygenase-1 
(HO-1, encoded by HMOX1 gene localized on chromosome 22q12) [26- 30]. HO-1 is a 
heme-degrading enzyme yielding ferrous iron, biliverdin and carbon monoxide. It exerts 
antioxidative and antiapoptotic effects in response to various cellular stressors [31]. In 
carcinogenesis, HO-1 has an ambiguous role [32- 34]. Even though it is essential for pre­
venting carcinogenesis in healthy cells through maintaining redox homeostasis [35], under 
the ongoing process of tumorigenesis, its activation becomes deleterious for patients, since 
its antioxidant, antiapoptotic, and anti-inflammatory properties promote proliferation and 
invasiveness of malignant cells, leading ultimately to protection of neoplastic cells from 
apoptosis [36], which was also observed in AML [29]. Furthermore, HO-1 regulates prolif­
eration and differentiation of many cell types [37- 44], and recently we have demonstrated 
that it also affects granulocytic development through influencing myelocyte prolifera­
tion [45], suggesting its potential role in regulating granulopoiesis under stress-induced 
conditions, such as chemotherapy.
In human, the level of inducible HO-1 response is controlled by polymorphisms in 
the gene promoter region [46]. Based on the (GT)n microsatellite length polymorphism, 
the HMOX1 promoter can be classified into three categories: short, medium and long [47]) 
and based on the various promoter lengths, six genotypes are derived: short/short (SS), 
m edium /short (MS), m edium /medium  (MM), long/short (LS), long/m edium  (LM), and 
long/long (LL) [48], affecting both basal and induced levels of HO-1 expression [49]. Since 
the long (GT)n sequence has the potential to acquire thermodynamically unfavorable 
Z-DNA conformation [46], therefore, short alleles were shown to be associated with in­
creased transcriptional activity, higher inducibility and enhanced HO-1 enzymatic activity 
in numerous biological and clinical studies [46,47,49- 55]. Interestingly, it was also demon­
strated in lymphoblastoid cell lines that the cells with short (GT)n repeats exhibited an 
increased resistance to oxidant-induced apoptosis [51]. The association between HMOX1 
promoter polymorphisms and cancer susceptibility has been studied widely, but remains 
inconsistent [56]. Both LL genotype [52,54,57- 60] and SS genotype [61] were shown to 
increase risk of different cancers. The second type of polymorphism in HMOX1 gene is 
associated with an A (-4 1 3 )T  (rs2071746) single-base change [47,62]. In this case of SNP 
A (-413)T , it was suggested that the A might be associated with a higher promoter activity 
than the T allele [46,63], but the contradictory results were also published [64]. There 
are only a few studies investigating both types of polymorphisms (lengths and SNPs) 
simultaneously [65] and there are no data on the effect of certain polymorphic variants on 
the clinical course in cancer patients, including ALL patients.
The aim of this study was to investigate the impact of HMOX1 promoter polymor­
phisms on long-term clinical outcomes, the prevalence of childhood ALL, and the role of 
certain polymorphic variants in resistance to chemotherapy. Second, since HO-1 plays a 
role in granulopoiesis, and we have verified whether those polymorphisms may reflect a 
predisposition to CIN incidences in children with ALL.
2. Results
2.1. Length and A (-4 1 3 )T  SNP Polymorphisms and Risk o f Relapse
To investigate the long-term clinical impact of certain polymorphisms, we evaluated 
the trend of standardized log-rank statistics using relapse-free survival (RFS) time. Among 
patients with the SS genotype, 3 patients (37.5%) experienced relapse at mean time of 
30 months from the diagnosis. Among patients with the SL genotype, five patients (18.5%) 
experienced relapse at mean time of 30.4 months from the diagnosis. Among patients 
with the LL genotype, one patient (4.8%) experienced relapse at 19 months from the 
diagnosis. The proportion of patients who experienced relapse within certain subgroup 
(SS, SL or LL) did not reach statistical significance (p =  0.08). The five-year actuarial 
probabilities of RFS were 62.5%, 80.8%, and 95.5% for SS, SL, and LL group respectively, 
with the highest difference between SS vs. LL genotype (p =  0.022) (Figure 1A ). This 
analysis suggests that the presence of short alleles might be a risk factor for poor prognosis. 
However, the effect of length polymorphism on patients' overall survival (OS) did not 
reach statistical significance.
Among patients with the AA genotype, two patients (11.8%) experienced relapse at 
mean time of 20.5 months from the diagnosis. Among patients with the AT genotype, 
four patients (13.3%) experienced relapse at mean time of 32.5 months from the diagnosis. 
Among patients with the TT genotype, three patients (25%) experienced relapse at mean 
time of 30.3 months from the diagnosis. The proportion of patients who experienced 
relapse within certain subgroup (AA, AT or TT) was statistically insignificant. The five- 
year actuarial probabilities of RFS were 88.2%, 86.7%, and 75% in AA, AT, and TT group 
respectively, not showing statistical difference (Figure 1B). This analysis indicates that 
A (-413)T  polymorphism has no prognostic significance.
2.2. Co-Segregation o fA (-4 1 3 )T  SNP with Length Polymorphisms
In order to examine the co-segregation of the HMOX1 - 4 1 3  A > T SNP with (GT)n 
repeat polymorphisms we compared a percentage frequency distribution (frequency of AA, 
AT or TT genotype distribution, shown as a percentage of the total frequencies in all ana­
lyzed subjects divided on the basis of length polymorphism (Figure 2A )) and distribution 
of different (GT)n alleles in subjects homozygous in terms of TT or AA (Figure 2B ). Concor­
dantly with data obtained by Bean et al. [65], we found that both in healthy controls and in 
ALL patients, in almost all individuals short alleles occurred simultaneously with T alleles, 
and in most cases long alleles (29/30 GT) were present together with A alleles (Figure 2A). 
We also noticed that in the control group, very long alleles (>30 GT) exclusively occurred 
together with T alleles (Figure 2B). Because of this co-segregation, without simultaneous 
investigation of SNP and length polymorphisms, it is not possible to clearly identify which 
of the A or T alleles exhibit transcriptional activation properties. Due to this doubt, and 
also the fact that the length polymorphism function has been well documented, and that 
our data demonstrate its role in RFS, we postulate that only the length polymorphism, but 
not SNP, should be considered clinically significant.
Figure 1. Relapse-free survival by grouping; patients according to the presence of (A) length poly­
morphism and (B) SNPs polymorphisms. (A) The 5-year actuarial probability of relapse-free survival 
was 62 .5%, 80 .7% and 95.5% for pa tients with SS (red line, n = 8), SL (gray line, n = 26) and OL (black 
line, n = 22) genotype, respectively. (B) The 5-year actuarial probability of relapse-free survival was 
88.2%, 86.7% and 75% for patients with TT (red line, n = 12) genotype, AT (gray line, n = 30) and AA 
(black line, n = 17), respectively.
2.3. Distribution o f  the Length Polymorphisms and Acute Lymphoblastic Leukemia Prevalence 
Because the criOeria for distinguishingthe M and L alleles are inconsistent (different 
cutoffs ret arbitrary in different studips), and their presise distinction is not of biological 
and clinical importpnce, we analyzed our results applying only 2 allele categories iS and L), 
with a cuioff for S alleles of 23 or fewer dinucleotide repeats (<24), based on our earlier 
researchw here we experimenSally determined the cut-off -value in human endothelial 
cells, by measuring HMOX1 expression [49). Next, wie asnessed the frequency of the S 
and L alleles in aonOrol subjects and in patien8s (Figure 3A ). We found that L alleles were 
prevailing; over S alleles in both control and TALI, patients' groups. However, S alleles were 
statistically more frequent in ALL patients titan in healthy children (08.4% in ALL patients 





Figu re 2. Co-segregation of the A and T alleles with HMOX1 promoter length variants: (A) Shown 
as a percentage frequenay distribution of AA, AT and TT genotype in SS, SL and LL individuals 
(both patients and control group); (B) distribution of A A and TT in individuals with certain length 
■variants, separately in the patient and control group ; S—short alleles (GT n < 24), M—medium alleles 
(24-28 GT n), L—long alleles (29/ 30 GT n), L—very long alleles ((ST n > 30 ).
Then we compared the proportion of individuals with the SS, SL and LL genotype in 
the studied groups. Since it had previously been shown tha( one short allele would sulfice 
to provide higher activation of HMOX1 promoter [49,66], in the first step we combined 
individuals with the SS and SL genotypes into one group. We found that among ALL 
patients, the proportion of such individuals was statistically higher than in the control 
group of healthy people (62.5% in ALL patients; 38.1% in control group, p = 0.024 Figure 3B). 
Because in lymphoblastoid cell lines (LCLs) it was shown that HMOX1 mRNA expressions 
and HO-1 activities were significantly higher in cells with the SS genotype [67], in the next 
step we compared a proportion of homozygous SS individuals in studied groups. However, 
we did not find significant difference in the distribution of SS homozygotic individuals 
between ALL and control group (14.3% in ALL patients; 9.5% in control group, Figure 3B). 
These results indicate that the presence of the S allele (SS or SL genotype) may increase the 
risk of ALL leukogenesis, but the additional presence of a sec ond S allele (SS genotypie) is 
no longer relevant.
A
Figure 3. (A) Frequencies of short and long alleles in the patient and control groups. In ALL patients: 
43 short alleles (38.4%) and 69 long alleles (61.6%); in control group: 20 short alleles 623.8%) and 
64 long; alleles (76.2%). (B) Comparison o1 percentage o6 patients and healthy controls -with the SS, 
SL or LL genotype. In ALL patients: SS genotype—8 patients (14.3%), SL genotype—27 patients 
(48.2%), LL genotype—26 patients (67.5%). In controls group: SS genotype— 4 individuals (9.5%), 
SL genotype—12 individuals (28.6%), LL genotype—26 individuals (6S.9%). *—p < 0.05.
2.4. Length Polymorphisms and Treatment Response
Next, we found diffeeent feequency of thee S and L alleles in thee risk-adjusted patient 
groups 5p = 0.144). The frequency of the S alleles was increaeed concomitantly with rising 
risk st-atifi-ation in the geoups, with a statistically higher feequency of flee S alleles in HR 
patients w h in  eompared to fhe eontrol group (p =  0.003) or to the SR geoup 5p =  0.041 ) 
(123.8% in thee eontrol geoup; 1281.1% in thee SR geoup; 36.7% in thee IR group; 60% in thee HR 
group, Figure 4A ). Next, we compaeed thee peoportion of thee SS, SL, and LL genotypes in 
thee patients versus the control group, and found an unequal distribution of those genetypes 
(p = 0.0141). W hen we combine individuals with the SS an d S e  genotypes (as indm duals 
with at least ene short allele) and compared theia proportion between ehe risk groups, we 
found the highest number of such patients in the HR group, with significant difihrence 
when compared to the control group (p =  0.031) (38.1% an the control group*) 56.6% in 
the SR group; 60% in the IR group; 80% in the HR, Figure 4B ). Next, we compared the 
proportion of homozygous SS individuals in all studied groups. The highest proportion of 
homozygous SS genotype was observed in the HR risk group, with significant difference 
when compared to healthy control (p = 0.035) and to the SR group (p = 0.014) (9.5% in the 
control group; 0% the SR group; 13.3% in the IR group; 40% in the HR group, Figure 4B). 
These results indicate that the presence of short alleles, especially in the homozygous
Ishort alleles 
Hong alleles
configuration, is associated with stratification to the HR group, reflecting a higher risk of 
treatment failure, coherent with a higher risk of relapse (Figure 1A ).
Figure 4. (A) Frequencies of short and long alleles in the control group and in patients stratified 
into the risk groups. In the control group: 20 short alleles (23.8%) and 6-4 long; alleles (76.2%); in 
the SR group: 9 shorl alleles (28.1%) and 23 long alleles (71.9%); in the IR group: 22 short alleles 
(36.7%) and 38 long alleles (63.3%); in the HR group: 12 short alleles (60%) arid 8 long alleles 
(40%); (B) Comparison ol percentage of individuals with the SS, SL and LL genotypes in the control 
group and in patients stratified into the particular risk groups. In the control group: SS genotype— 
4 individuals (9.5%), SL genotype—12 individuals (28.6%), LL genotypie—26 mdividuals (61.9%). In 
the SIR group: SS genotype—0 patients, SL genotype—9 patients (56.2%), LL genotypie—7 patients 
(43.8%). In the IR group: aS genotype— 4 patients (13.3%), SL genotype— 14 patients (46.7%), 
LL genotype— 12 patients (40%). In the HR group: SS genotype— 4 patients (40%), SL genotype— 
4 patients (40%), LL genotype—2 patients (20%). *—p < 0.05; **—p < 0.01.
We also investigated whether the presence of the S allele could indeed lead to a higher 
blast cells persistence, measured as MRD. On the 15th day of treatment there was no 
statistical difference in blast count between patients characterized by the presence of at 
least one S allele (data not shown). However, on the 33rd day, in the IR group we found 
that SS/SL  patients exhibited higher MRD values (p  = 0.009, Figure 5A). Nevertheless, as 
the difference was found only in the IR group, and only at day 33rd, we doubt that these 







Figure 5. (A) MRD level at 33rd day? of treatment in association with the presence of short alleles in 
patients, shown iit all patients and separately in patients atratified into the partitular risk groups. 
Mean MRD was 0.086 ±  0.17 inpatients ■with at least one S allele versus mean MRD 0.0033 ±  0.006 in 
the LL patients. In the SR group—data available for 15 patients, in the IR group for 28 patients, in 
the HR group for 10 patients. (B) CIN incidences in association with the presence of short alleles in 
patients, shown in all patients, and separately in patients stratified into tire particular risk groups. 
Then the influence of genotype and a risk group was calculated as independent varisbler on a number 
of CIN incidents. It appeared that the main etfect resulted irom the risk group (two-way ANOVA, 
p = 0.0005), but there was also an effect oi genotype (p = 0.0)0)55). In the SR group—dsta avaflaRle tor 
15 patients, in the IR group for 24 patients, in the HR group for 10 patients. Data are presented as 
means and SEM * p < 0.05, ** p < 0.01.
2.5. Chemotherapy-Induced Neutropenia (CIN)
Subsequently, we checked whether the frequencyof G-CSF administration cycles, 
which reflects the number of CIN incidents in a patient, was related to the presence of 
the certain HMOX1 promoter allele. In the first step, the analysis was carried out in all 
patients, regardless of the risk group. It was found that patients with the S allele had signif­
icantly more neutropenic events thaS had fo be treated by? administering G-CSF (p = 0.048, 
Figure 5B). However, in the HR group, most G-CSF administrations are pre-scheduled in 
advance, and in the SR and IR groups G-CSF is administrated if necessary. Because the 
genotype itself relates to the risk groups, we examined the influence of genotype and risk 
group on a number of CIN incidents as independent variables. We found that the main 
effect resulted from the risk group (two-way ANOVA, p <  0.001), but we also found the 
effect of genotype (p = 0.006). Since each risk group is treated with a different therapeutic 
protocol, and a given type of chemotherapeutic regimens may per se predispose to a differ-
ent occurrence of CIN, the analysis was also conducted separately in the risk subgroups. 
Accordingly, in all risk groups the number of cycles of G-CSF treatment tended to be 
lower among children with the LL genotype, however it was not statistically significant
(Figure 5B).
2.6. HO-1 Expression and Its Localization within Normal Human Hematopoietic System
In the last set of experiments, we wanted to assess a possible biological mechanism 
responsible for a distinct clinical course in patients with different length polymorphisms of 
HMOX1 promoter. We wanted to assess whether it might be associated with the role of 
HO-1 in the blast cells per se, or rather in the myeloid compartment.
Since the physiologically relevant HO-1 suppressor—heme-regulated BACH2— is a 
critical negative mediator at the pre-B cell receptor checkpoint and is a safeguard against 
leukemogenesis, we addressed the question whether HO-1 might also play a role in 
physiological lymphopoiesis. For this purpose, we examined the HO-1 expression and 
its localization within normal human hematopoietic system. We sorted cells of specific 
immunophenotype and stained HO-1 protein to check its expression by means of confocal 
microscopy. To distinguish human hematopoietic progenitor subsets, the staining scheme 
described by Seita et al. was employed [68]:
1. Hematopoietic stem cells (HSC): Lin- CD34+CD38- CD90+CD45RA-
2. Multipotent progenitors (MPP): Lin- CD34+CD38- CD90- CD45RA-
3. Common lymphoid progenitors (CLP): Lin- CD34+CD38- CD10+
4. Common myeloid progenitors (CMP): Lin- CD34+CD38+CD123+/lowCD45RA-
5. Megakaryocyte-erythroid progenitor (MEP): Lin- CD34+CD38+CD123- CD45RA-
6. Granulocyte-macrophage progenitor (GMP): Lin- CD34+CD38- CD123+CD45RA+
7. Lymphoid maturation steps were established based on:
- preBI: CD19+CD34+CD10+CD20-
- preBII: CD19+CD34- CD10+CD20dim
- Immature B cells: CD19+CD34- CD10+CD20+
- Mature B cells: CD19+CD34- CD10- CD20+
Interestingly, we found that in hematopoietic stem cells and in progenitors committed 
to granulocyte or megakaryocyte lineage HO-1 is mainly located in the nucleus, what 
may indicate its non-canonical, non-enzymatic role [69]. However, upon maturation into 
preB-I stage of B-cell development (the stage of normal B-cell development, which is most 
prone to malignant transformation into BCP-ALL (the pre-pro-B to pre-BI transition) [70], 
HO-1 expression was barely detectable (Figure 6). This was consistent with the fact that 
BACH2—HO-1 suppressor— is upregulated at the transition from multipotent progenitor 
(MPP) into the B cell lineage, before the completion of the heavy chain checkpoint [71]. 
These data suggest that in physiological conditions HO-1 expression is not required for the 
maturation of B-cell precursors.
2.7. HO-1 Expression in Peripheral Blood and Bone Marrow Cells before and during Chemotherapy
To check whether chemotherapy protocols used in ALL patients actually induce 
HO-1 expression in normal cells, regardless of the presence of leukemic cells, HMOX1 
mRNA level was measured in peripheral blood samples taken from ALL patients during 
treatment course, but at the stage of clinical remission, when no blast cells were found 
in the peripheral blood, and complete blood count was normalized. We found that in 
comparison to healthy, untreated children, in ALL patients the level of HMOX1 mRNA 
was significantly elevated (p = 0.017, Figure 7A). It must be noted, however, that HMOX1 
mRNA measurements were performed in samples taken from patients at various stages 
of treatment (including patients just before the end of treatment or after the end of entire 
treatment course). Hence, in this case many additional factors might have influenced the 
elevation of HMOX1 expression, not solely the chemotherapeutic agents.
stages of development of B cells, 
in which A LL  arises
Figure 6. Confocal microscopy slides displaying HO-1 protein (green) and nuclea r staining; (blue) in normal bone marrow 
hematopoietic stem and myeloid progenitor cells, as well as B-cell developmental itages. HSC—hematopoietic stem 
cells, MPP—multipotent progenitors, CMP—common myeloid progenitors, GMP—granulocyte-macrophage proginitor,
MEP—megakaryocyte-erythroid progenitor, CLP—common lymphoid proieniaor.
In the next step we compared the level of HO-1 expression (presented as mean fluo­
rescence intensity—MFI) in certain cell subsets within bone marrow at the day of diagnosis 
(prior to treatment— day 0) and on days 15 and 33 of treatment. To exclude cellular debris, 
only nucleated cells (syto41+) were taken into analysis. Leukemic blasts were identified 
as immature B cell population with aberrant immunophenotype, defined individually for 
each prtient (leukemia associited immusophenotype—LAIP). Normal mature B cells were 
defined as cells within "lym phgate" (bright CD45 expression, low SSC) positive for CD1 9 
and CD20 but negativefor CD10 and CD34. Erythroblasts w eredefined as cells negative 
for CD-IS with low SSC characteristic!, simultaneously nagative for CD11a, CD19, CD10, 
CD34, and CD20. Monocytes were defined as cells within "m onogate" (bright expression 
of CD45 and intermediate SSC), negative for CD19, CD10, CD20, positive for CD38, with 
vety bright CD11a eapression. Each population was backgated on FSC/SSC dotplot.
At the day oi diagnosis we compared the HO-1 MFI between leukemic cells and the 
resipual normal cell subsets presant in the sample (Figure 7B). We found that HO-1 expression 
was the lowest in leukemic bleste, with comparabile level ef exprestion as in erythroblasts. 
The expression of HO-1 in mature B-cells was slightly higher than in the blast cells (p = 0.004), 
and erythroblasls (p = 0.048). The highest HO-1 expressionwas detected ie monocytes when 
compared to all analyzed subsete (monocytes in cumparison: to blast cells— p <  0.0001, 
to mature lymphocytes B—p =  0.0002, and to erythroblasts—p = 0.0001). This pattern of 
HO-1 expression in nan-malignant cells was similar to paitern of Hmox1 mRNA expression 
described in murine hematopoiesis model [72]. As HO-1 is a stress inducible enzyme, we 
have investigated whether HO-1 expression is indeed elevated in patients during induction 
chemotherapy, as at this poini the re im en  intensiiy is the same, regardless of the risk graup. 
This analysii was dona in six patients at day 15th in d  only three patients at day 33rd, as 
in ahe remaining thrae patients there was an insufficisnt amount of sample (due to aplastic 
bone marrow) to perform additional stainings, apart from routine MRD measurement. Only 
in monocytes was the HO-1 level statistically higher during following induction cycles 
(two-way Anova wish Bonferrom jeosttests, Figure 7C), we performed harther analysis 
tracking1. relative changes of H O 4 level in individual patients with distinct early treatment
response (Figure 7D). We found that the higher the fold increase of HO-1 in monocytes was 
observed, the higher level of MRD detected. Based on both HO-1 level directly measured 
in monocytes at dvys 15th end 33rdas well as relative HO-1 level changes in individual 
patients with different early treatment response (expressed as MRD level), we postulate that 
the altered HO-1 expression in bone marrow monocytes—but not in lymphocytes— may 
represent a response to stressful conditions, rather reflecting; modulation of HO-1 in the 
tumor microenvironment as a potential mechanism of chemotherapy resistance.
Figure 7. (A) Comparison of HMOX1 mRNA level in peripheral blood samples taken from healthy, untreated children 
(n = 3) end from ALL children (n = it*) during; treatment course, at stage of clinical remission w henno blast cells were 
found in the blood, and complete blood count was normalized. (B) Basal HO-1 expression (shown as MFI) in leukemic 
cells and the residual normal cell subsets present in the sample at the day of diagnosis (n = 11). (C) MFI of HO-1 in each 
cell subset before treatment (n = 11) and at day 15th (n = 6) and 33rd (n = 3) of induction. (D) The fold increase of HO-1 
expression in monocytes in relation to the risk group and to treatment response, expressed as MRD level. Blasts—leukemic 














2.8. Supplementary Information—A-SNP-T Polymorphism
Because cut-off point criteria of short, medium and long alleles are inconsistent, we 
also demonstrated our data as raw values (Supplementary Figure S1). The investigation of 
A (-413)T SNP (Supplementary Figure S2) revealed no significant difference in the T and A al­
leles frequencies in ALL patients compared to the control group (Supplementary Figure S3A). 
We also compared the proportion of the AA, AT and TT genotypes in patients and controls and 
we did not find statistically significant difference (Supplementary Figure S3B). Similarly, the 
frequency of alleles A and T between the risk groups was not altered significantly, as well as 
the proportion of patients with certain genotype AA, AT or TT (Supplementary Figure S4A,B). 
In the HR group there were only slightly more patients displaying at least one T allele or 
displaying homozygous TT genotype. However, this result can be attributed to the effect of 
co-segregation of the T allele with short alleles (which were predominant in the HR group), 
than to regulatory properties of the T allele per se. Since in contrast to unequivocal S allele 
distribution, the final distribution of T allele in patients was balanced by the presence of 
T alleles co-segregated with very long alleles in control group, the difference between the 
groups was lost.
3. Discussion
Given the concerns about the two most important barriers for survival of BCP-ALL 
children— therapy resistance and treatment-induced toxicities—the research on predictive 
markers is of great interest to further guide clinicians on dose individualization during 
personalized therapy. Recently, some studies explored the prognostic significance of 
HO-1 expression in human cancers, as well as its possible correlation with tumor clinical 
features and outcome [73]. The HO-1 expression depends on common HMOX1 promoter 
polymorphisms [74,75]. Because such a universal modulatory mechanism seems to be an 
accurate, objective, easy to perform, and a convenient routine clinical utility, we decided to 
verify the role of HMOX1 promoter polymorphisms as prognostic marker candidates in 
BCP-ALL children. It has been confirmed in several studies (also from our group: [49]) that 
HO-1 expression depends on the length of microsatellite sequences in HMOX1 promoter. 
The lower number of GT repeats allows for a higher HO-1 expression under control 
conditions and a stronger induction in response to stress. [46,47,50]. Several clinical studies 
have demonstrated that the length of GT region is associated with increased susceptibility to 
some human diseases [46]. In contrast, only sparse research has investigated an A (-413)T  
SNP in terms of clinical investigations [76] and its impact on HMOX1 transcription. To 
exacerbate, they provide contradictory results, indicating that either A [63] or T [64] is 
responsible for a higher transcriptional activation. Therefore, in this study we performed 
both genotyping of the (GT)n microsatellite polymorphism and A (-4 1 3 )T  SNP in the 
HMOX1 gene promoter in patients with BCP-ALL and in control group of healthy children.
In accordance with the previous data [65], we found high co-segregation of specific 
subtype of (GT)n microsatellite polymorphisms with A (-413)T  SNP variants, both in the 
control group and in ALL patients. Subjects carrying the most common subtype of L allele 
(29-30(GT) repeats) possessed mainly A allele, whereas individuals with short (<24 GT) 
or very long (>30 GT) alleles exhibited very high prevalence of T variant of SNP. 100% 
co-segregation of the homozygotes SS (considered as more transcriptionally active) with 
homozygous TT (regarded as less transcriptionally active), and the co-segregation of the 
most common type of L allele (shown to have low transcriptional activity) with the A 
allele, might lead to a conclusion that both types of polymorphisms occur usually in a 
configuration that abolishes their mutual effects. Importantly, most of the research on 
the clinical significance of SNP polymorphism has not simultaneously investigated the 
length polymorphisms, so it cannot be ruled out that the described differences, attributed 
to the certain SNP, could have in fact resulted from co-segregation of SNP with the specific 
subtypes of length promoter allelic variants which has a predominant role. Only the 
comparison of homozygous SS patients and homozygous AA or TT patients would fully 
answer the question. However, the coexistence of the SS alleles with the AA alleles is
extremely rare [65], and in our study group there were no patients with such genotype. Due 
to this inconsistency and difficulties in SNP polymorphism interpretation, we postulate that 
only the GT microsatellite polymorphism can be considered clinically significant. Analyses 
carried out as a part of this work also proved the lack of clinical relevance of A (-4 1 3 )T  
SNP variants, as there were no differences in RFS rate and A (-4 1 3 )T  SNP distribution 
among the studied groups.
In its important to note that the literature does not propose consistent classification of 
the (GT)n length polymorphism [48]—while some studies comprise to "short" category 
alleles shorter then 25, it was confirmed in molecular studies that promoter with less than 
24 (GT) repeats shows both increased HO-1 basal promoter activity and elevated response 
to stimuli [46,47,49,50]. Hence, in this work, we also used the cut-off <24 GT as "short" 
category. However, after recalculation of data using cut-off point less than 25 GT, we also 
obtained a very similar distribution of results, since there were very few patients with 
the 24 GT allele (data not shown). In term of category "m edium " and "long" the exact 
cut-off point varies even more between studies [46,47,50]. However, precise discrimination 
between these alleles does not bring any additional information, as it was confirmed 
that biologically important modulation of HO-1 activity depends on the presence of the 
short allele [49,66]. Hence, in this study, we also focused on the classification of HMOX1 
promoter based on short and long alleles.
First, we examined the association of polymorphic variants of the HMOX1 promoter 
with RFS. We found that patients with the SS genotype display the poorest RFS, especially 
when compared with the LL genotype. The SL genotype displayed intermediate risk of 
relapse. We also analyzed the length polymorphisms in association with childhood ALL 
prevalence. We demonstrated that in comparison to the control group, in BCP-ALL patients 
both the S (GT)n allele frequency and the proportion of patients with at least one S allele (SS 
genotype combined with SL as one group) were higher. However, there was no difference 
in the proportion of patients and controls with the SS genotype. It indicates that short, more 
active variants of the HMOX1 promoter, not only do not protect against the initiation of 
leukogenesis, but on the contrary, may even promote carcinogenesis. Studies on the associa­
tion between the HMOX1 promoter polymorphism and the prevalence of different types of 
cancer in humans are inconsistent, showing that the same allelic variants seem to be protec­
tive against one type of cancer, while posing high risk for other types [52,54,56- 61,77- 79]. 
Some discrepancies in the HMOX1 promoter polymorphisms and cancer prevalence may 
stem from a complex physiological role of HO-1, variability of its expression in different 
tissues (http://w w w .proteinatlas.org/EN SG 00000100292-HM OX1/tissue), and cell-type 
specific effects of HO-1 on cell differentiation [44,80]. This is especially true for such a 
complex and heterogenous tissues as bone marrow, where HO-1 is differently expressed in 
hematopoietic stem and progenitor cells and niche residing cells [72,81].
Although HO-1 is known to be critical for proper antibody production [82] little 
is known about its function in early B-cells development. Interestingly, its suppressor— 
BACH2 which is up-regulated at the transition from multipotent progenitor (MPP) to 
the pro-B [71]— has been shown to execute negative selection of premalignant early B 
cells that failed VH-DJH rearrangements at the pre-B cell receptor checkpoint. As it was 
previously suggested that loss of BACH2 in both normal pre-B cells and pre-B ALL may 
lead to leukemia [83], one could expect that HO-1 would be in turn elevated in leukemic 
cells. However, we found even decreased level of HO-1 in leukemic blasts in comparison 
to normal B cells and to monocytes. In normal bone marrow cells HO-1 was present from 
the stage of HSC, through MPP till CLP and after commitment to B lineage (at preB-I stage) 
HO-1 was barely detectable till the stage of mature B-cell (in contrast to the progenitors 
committed to granulocyte or megakaryocyte lineage). These findings were also consistent 
with the observation made in a murine model, showing that Hmox1 mRNA level was 
extremely low at B-cell progenitor stage [72]. As HO-1 was almost undetectable at the 
stage which is most vulnerable to malignant transformation into BCP-ALL (the pre-pro-B 
to pre-BI transition [70]), and in the malignant cells its expression was very low, we doubt
that HO-1 may play a significant role in protection of B progenitors from leukogenesis. 
Although it is highly unlikely that the presence of certain type of the promoter allelic 
variants affects HO-1 expression in B-cells and in leukemic blasts, it cannot be however, 
ruled out that HO-1 activity in stromal cells may indirectly affect B-cells e.g., through 
modulation of the level of free heme and iron availability in microenvironment [84,85].
HO-1 may be strongly induced in response to radiation, photodynamic therapy, or 
chemotherapy [33], pointing out the role of HO-1 in cancer chemoresistance [51]. As a 
better understanding of the mechanisms associated with resistance to therapy is essential to 
prevent tumor relapse, in the next step we checked the HMOX1 (GT)n genotype distribution 
within BCP-ALL patients, depending on their relapse-risk group. We found that the 
frequency of the S alleles was higher is the HR group compared to the control group, as 
well as to the SR group. Subjects possessing at least one S allele of the HMOX1 promoter 
were more frequently classified into the HR group than to the SR and IR groups. The 
HMOX1 SS (GT)n homozygous genotype occurred mostly in the H R group, and has not 
been observed in the SR group. Additionally, leukemic blasts evaluation revealed that 
patients from the IR group, who carried at least single S allele, exhibited higher MRD at 
the 33rd day of therapy, which is consistent with the fact that drug resistance in vivo is 
reflected by the MRD level [1- 3]. However, because in another risk group and at day 15th 
we did not observe a similar relationship, this observation may be biologically irrelevant.
Interestingly, HO-1 overexpression has recently been reported to negatively modulate 
glucocorticoid receptor pathways in prostate cancer cells [86], and glucocorticoids (pred­
nisone and dexamethasone) play an essential role in the treatment of acute lymphoblastic 
leukemia (ALL) [87]. In our study, we did not find a significant difference in prednisone 
response between patients with certain HMOX1 (GT)n genotype (data not shown). How­
ever, we showed that, in BCP-ALL children, chemotherapy upregulates HO-1 at both 
mRNA level (in total peripheral blood cells) and at protein level (selectively in monocytes 
and not lymphoid cells). Monocytes play an important role in mesenchymal stromal cell- 
driven immunomodulation. They differentiate into regulatory macrophages and produce 
many cytokines [88]. Therefore, we assume that HO-1 shifts in monocytes may also reflect 
macrophage polarization response and— to some extent— may represent shifts in stromal 
compartment. Hence, we speculate that unequal allelic variant distributions in BCP-ALL 
patients may be more important in stromal compartment. This supposition could be veri­
fied only by examination of trephine biopsy specimens, which are not taken routinely in 
ALL patients. Nevertheless, many studies have convincingly reported the role of HO-1 in 
tumor progression [74,89- 94], pointing to its significance not only in tumor cells per se, but 
also in stromal compartment, particularly in the tumor-associated macrophages [95- 98].
Interestingly, macrophages have also been shown to have a role in the mobilization of 
hematopoietic cells into the peripheral blood by G-CSF [99,100], and HO-1 induction has 
been reported to impair granulocyte mobilization [101]. Cytotoxic chemotherapy itself sup­
presses the hematopoietic system, dysregulating the physiological granulocyte proliferation 
and differentiation [102], and leading to chemotherapy-induced neutropenia (CIN) [11]. 
Hence, in the last step we investigated the effect of (GT)n microsatellite polymorphism on 
susceptibility to CIN incidents. We found that subjects with at least one short allele variant 
had significantly higher CIN incidents. Because different chemotherapeutic protocols are 
used depending on the risk group classification, we checked the length polymorphism 
distribution in BCP-ALL patients within different risk categories. However, only in the IR 
group did patients who carry at least single S allele reach a significantly elevated number 
of CIN incidents, most probably due to the fact that this group was the most numerous.
Under stress conditions, rapid enhancement of granulopoiesis is predominantly regu­
lated by G-CSF-responsive transcription factor C /EBPß [103]. C /EBPß enhances prolifera­
tion [104], leading to fast adaptation of hematopoietic system to stress response [105]. A 
study by Suh et al. indicated that activity of C /E B P  transcription factors can be inhibited 
by carbon monoxide (Suh, Jin et al. 2006), which was later confirmed by our group for 
C/EBPÓ [44]. We have also shown a similar mechanism of indirect modulation of C/EBPß
in granulocytic development in HO-1 knock-out mice [45]. As HO-1 degrades heme with 
concurrent release of carbon monoxide, its increased expression governed by the short 
(GT)n variant of HMOX1 promoter, might indirectly influence granulocyte maturation 
and myelocyte proliferation via C /EBPß mediated pathway. In line with these results, we 
suppose that short allelic variant of (GT)n HMOX1 promoter predisposes ALL patients 
to higher number of CIN incidents, and thus may help identify patients at greater risk 
for such complications. The suggested HO-1-dependent mechanism does not appear to 
be specific for certain drug, but is generally driven by oxidative stress, being one of the 
putative pathways that affect susceptibility to chemotherapy-induced myelosuppression.
Because genetic variations can be used to predict drug toxicity, safety, and effi­
cacy [19,106], there have been attempts to identify patients at greater risk for CIN. In­
terestingly, genome-wide association studies (GWAS) performed in Japanese patients 
failed to identify genetic variants associated with CIN susceptibility that surpassed the 
genome-wide significance level [18]. However, only SNPs, but not microsatellite length 
polymorphisms, were investigated. Concordantly, in our study, we also did not find an 
association between SNP in the HMOX1 promoter and CIN incidences (data not shown).
The limitation of our research is the relatively small number of patients. However, as 
our main aim was to check the influence of the HMOX1 gene promoter polymorphisms on 
the treatment response and its toxicity, we selected a group of patients in whom the entire 
treatment protocol had been completed and the long follow-up data were available. Al­
though this research brings some new data related to important therapeutic complications 
of ALL treatment, some of our results are of borderline statistical significance, hence they 
should be confirmed in larger study.
In summary, we described the effect of HO-1 and HMOX1 gene promoter polymor­
phisms on the ALL development, chemotherapy resistance and patient risk to CIN inci­
dents. We found that only (GT)n microsatellite polymorphism, but not A (-413)T  SNP, is of 
clinical relevance. The presence of the short (GT)n allelic variant of the HMOX1 promoter 
correlates with a higher risk and worse prognosis for ALL patients, and is associated with a 
higher rate of CIN incidents. Therefore, we propose that the presence of the short HMOX1 
alleles might help identify the high-risk patients. It also appears that the potential use of 
HO-1 inhibitors might be considered as a supplementary strategy in the treatment of ALL.
4. Materials and Methods
4.1. Patients
The study group comprised of 60 children with BCP-ALL treated in the Oncology and 
Hematology Department at the University Children's Hospital of Krakow, between 2007 
and 2015 with ALL IC-BFM 2002 or ALL IC-BFM 2009 therapeutic protocols. Patients were 
stratified into standard (SR, 18 patients, 30%), intermediate (IR, 32 patients, 53.3%) or high 
risk group (HR, 10 patients, 16.7%) based on the response to chemotherapy and disease 
characteristics (i.a. genetic factors, prednisone response). Children who had developed 
chemotherapy-induced neutropenia (CIN) were treated with G-CSF 24 h following incident 
until the neutrophil count achieved the level of at least 1 0 0 0 /pL. G-CSF regime ranged 
from 3 days to a maximum of one week. The frequency of CIN incidences in each patient 
was recorded. The control group comprised 42 children. Control group was selected 
from children referred to immunological outpatient clinic with upper respiratory tract 
infections, in whom after routine clinical and laboratory follow-up immunodeficiency 
was excluded. The study was approved by the Bioethics Committee of the Jagiellonian 
University (K B E T /76 /B /2014 , 24 April 2014) and informed consent was obtained for 
all patients.
4.2. Patients' Samples
Peripheral blood (PB) and bone marrow (BM) of patients were analyzed. BM samples 
were analyzed at 15th and 33rd days of treatment to assess the minimal residual disease
(MRD) by multicolor flow cytometry. PB samples were taken by the end of treatment to
assess HMOX1 promoter polymorphisms and mRNA level.
4.3. DNA Isolation
DNA isolation was performed using Syngen Blood/C ell DNA Mini Kit according 
to the manufacturer protocol. Final DNA concentration was measured using NanoDrop 
spectrophotometric technique (Thermo Fisher Scientific, Wilmington, DE, USA).
4.4. Length HMOX1 Gene Promoter Polymorphism
In order to assess the number of (GT)n repeats in the HMOX1 promoter region PCR 
reaction was done using GoTaq®G2 Flexi DNA Polymerase Kit (Promega, Madison, WI, 
USA) and the following pair of primers was applied: Forward: 5'-AGA GCC TGC AGC 
TTC TCA GA-3', Reverse: 5'-ACA AAG TCT GGC CAT AGG AC-3', where forward 
primer was labeled with 6-carboxyfluoresceine (FAM). PCR reaction was conducted under 
following conditions: 95 °C for 60 s, 37 cycles of 95 °C for 30 s, 58 °C for 15 s, 73 °C 
for 30 s and final elongation 73 °C for 45 s. DNA fragments analysis was performed 
by capillary electrophoresis (ABI PRISIM® 310 Genetic Analyzer, Applied Biosystem, 
Foster City, CA, USA) with GeneScan™  350 ROXTM dye Size Standard. Fragments sizes 
were determined with ABI Prism program (Gene Scan Analysis and Genotyper Software, 
Applied Biosystems, Foster City, CA, USA). In two patients from the SR group and in 
two patients from IR group, due to technical reasons it was impossible to determine length 
polymorphism, so data on length polymorphism are available for 56 children.
4.5. SNP HMOX1 Gene Promoter Polymorphism
For identification of SNP A (-413)T  polymorphism PCR (GoTaq®G2 Flexi DNA Poly­
merase Kit (Promega, Madison, WI, USA)) was used with following primers and reaction 
conditions, Forward: 5'- GGA TGA ACC ATG AAA ATA CTA GAG TC-3', Reverse: 5 '-ATT 
TTG CTC CTT CCA GAG C-3'; 95 °C for 10 min, 34 cycles of 95 °C for 30 s, 56.1 °C for 30 s, 
72 °C for 60 s and final elongation 72 ° C for 10 min. To remove remaining primers and 
free nucleotides Exonuclease I treatment of PCR products was conducted using Exo-BAP 
Kit (Eurx, Gdańsk, Poland) for 15 min in 37 ° C, followed by heat inactivation for 15 min 
in 80 °C. Sequencing PCR reaction was performed with BigDye® Terminator v3.1 Cycle 
Sequencing Kit under conditions: 95 °C for 10 min, 25 cycles of 95 °C for 10 s, 50 °C 
for 5 s and 60 °C for 4 min. PCR products purification was carried out with BigDye® 
X-Terminator Purification Kit (Applied Biosystems, Foster City, CA, USA). DNA fragments 
sequencing was analyzed by means of capillary electrophoresis AB3500 Genetic Analyzer 
(Life Technologies, HITACHI, Tokyo, Japan). In one patient from IR group, due to technical 
reasons, it was impossible to determine SNP polymorphism. Data on SNP polymorphism 
are available for 59 patients.
4.6. Cell Sorting, Immunofluorescent Staining and Confocal Analysis
In order to prepare immunofluorescence slides of certain hematopoietic stem or 
progenitor cell subsets, characterized elsewhere [68,107], normal BM samples were stained 
using following primary antibodies: Lin-FITC, CD90-PE, CD34-APC, CD38-AlexaFluor700, 
CD45-APC-H7, CD45RA-PE-Cy-7 or CD38-FITC, CD34-PE, CD19-APC, CD20-APC-H7 
(BD Biosciences, San Jose, CA, USA). Cells of defined immunophenotype were sorted 
using MoFlo-XDP cell sorter (Beckman Coulter, Brea, CA, USA) into 20 mL PBS drops 
on poly-L-lysine coated slides. After settling, cells were fixed with 4% paraformaldehyde 
and permeabilized with 0.1% Triton X100. Afterwards, samples were incubated with 
0.25% glycine for 30 min, followed by blocking with 3% BSA in PBS for 1 h. Subsequently, 
samples were stained overnight at 4 °C with primary antibodies recognizing HO-1 (rabbit 
polyclonal, SPA 896, Enzo, Warszawa, Poland) in a moisture chamber. After 5 washing 
steps, slides were incubated with goat anti-rabbit secondary antibody conjugated with 
Alexa Fluor 488 (Life technologies, Carlsbad, CA, USA) and DAPI for 1 h in darkness. After
the next 5 washing steps, cells were analyzed using a Zeiss confocal microscope with ZEN 
Software (Zeiss, Oberkochen, Germany).
4.7. RNA Isolation, qRT-PCR
RNA isolation was performed using RNeasy® Mini Kit. Reverse transcription and 
polyadenylation reaction were carried out with NCode™ VILO™ miRNA cDNA Synthesis 
Kit (Life Technologies, Carlsbad, CA, USA). Quantitative PCR reaction was conducted 
with StepOne Plus cycler (Applied Biosystems, Foster City, CA, USA) and SYBR Green 
JumpStart™ Taq ReadyMix™ (Sigma-Aldrich, St. Louis, MO, USA) under the following 
conditions: 95 °C for 10 min, 40 cycles of 95 °C for 30 s (denaturation), 60 °C for 60 s 
(starters annealing), 72 °C for 45 s (elongation) and 72 °C for 10 min (final elongation). 
The following primers were used: for HMOX-1 Forward: 5'-TTC TTC ACC TTC CCC 
AAC ATT G-3', Reverse: 5'-CAG CTC CTG CAA CTC CTC AAA-3', and for EF-2 Forward 
5'-GAG ATC CAG TGT CCA GAG CAG-3' , Reverse 5' -CTC GTT GAC GGG CAG ATA 
GG-3' as an endogenous control.
4.8. MRD Detection Using Flow Cytometry
Multicolor flow cytometry analysis of BM was performed at the day of diagnosis to as­
sess leukemic-associated immunophenotype (LAIP) of blasts cells. A following antibodies 
were used for cell immunophenotyping: CD34-PE, CD45-PerCP, CD10-PE-Cy7, CD19-APC, 
CD38-AlexaFluor-700, CD20-APC H7, CD11a-BV510 (BD Biosciences, Waltham, MA, USA), 
CD58 (Beckman Coulter, Brea, CA, USA). On the day 15th and 33rd BM was analyzed 
using the same panel of antibodies to determine MRD. To the appropriate amount of BM 
(106 cells) antibodies listed above were added, samples were incubated for 20 min at room 
temperature in darkness. Erythrocytes were lysed for 10 min at room temperature in 
darkness with lysing solution (BD FACS Lysing Solution, Becton Dickinson Biosciences, 
San Jose, CA, USA), washed twice in PBS, and finally resuspended in 200 pL of PBS. For 
distinguishing nucleated cells, samples were stained with Syto®41 (Thermo Fisher Scien­
tific, Waltham, MA, USA). FACS analysis was done using FACSCanto or FACSCanto10 
with FACSDiva Sorfware v. 8.1 (Becton Dickinson Biosciences, San Jose, CA, USA).
4.9. HO-1 Detection Using Flow Cytometry
HO-1 expression was assessed in BM of 11 patients upon diagnosis. Then in patients 
in whom, after routine MRD staining, there was a sufficient material for additional staining, 
an intracellular HO-1 staining was performed (6 children at day 15,3 children at day 33). In 
this purpose 106 of bone marrow cells were stained with CD34-PE, CD45-PerCP, CD10-PE- 
Cy7, CD19-APC, CD38-AlexaFluor-700, CD20-APC H7, CD11a-BV510 (BD Biosciences, San 
Jose, CA, USA), lysed, fixed, and then permeabilized using a BD Intrasure Kit, according 
to the m anufacturer's instructions. After permeabilization step, cells were incubated 
with primary antibodies recognizing HO-1 (rabbit polyclonal, SPA 896, Enzo, Warszawa, 
Poland), washed twice, and stained with goat anti-rabbit secondary antibody conjugated 
with Alexa Fluor 488 (Life technologies, HITACHI, Tokyo, Japan). After two washing 
steps, samples were stained with Syto®41 (Thermo Fisher Scientific, Waltham, MA, USA) 
and analyzed using FACSCanto10 with FACSDiva Sorfware v 8.0.1 (Becton Dickinson 
Biosciences, San Jose, CA, USA).
4.10. Statistical Analysis
The results were analyzed using GraphPad Prism 7 software (GraphPad Software, 
San Diego, CA, USA). Relapse-free survival (RFS) curves were drawn with Kaplan-Meier 
methods, and differences in curves were analyzed using the log-rank (M antel-Cox) test. 
To determine whether there is a significant difference between the observed frequencies 
in HMOX1 polymorphisms the Fisher's exact test was used. To compare the distribution 
between the two groups, the M ann-W hitney U test was used. To examine the influence 
of two different independent variables (a genotype and a risk group) on a number of
CIN incidents, two-way analysis of variance was applied. Differences were considered 
statistically significant if the significance level (p) was less than 0.05.
Supplementary Materials: Supplementary Materials can be found at https://www.mdpi.com/1422 
-0067/22/3/988/s1. Supplementary Figure S1. Distribution of length polymorphisms in control and 
patients, presented as actual number of GT repeats. Supplementary Figure S2. Electropherograms 
showing A(-413)T SNP polymorphisms. Supplementary Figure S3. (A) A and T alleles frequencies 
in patient and control group. In ALL patients: 64 A alleles (54.2%) and 54 T alleles (45.8%); in 
control group: 26 A alleles(58.1%) and 26 T alleles (41.9%), (B) Comparison of percentage of patients 
and controls having at least one A allele to TT genotype. In ALL patients: AA and AT genotype: 
47 patients (79.7%), TT genotype: 12 patients (20.3%); in control group: AA and AT genotype: 
24 individuals (77.4%), TT genotype: 7 individuals (22.6%), (C) Comparison ofpercentage of patients 
and controls with AA genotype. In ALL patients: AA genotype: 17 patients (28.8%), AT and TT 
genotype: 42 patients (71.2%); in control group: AA genotype: 12 individuals (38.7%), AT and TT 
genotype: 19 individuals (61.3%). Supplementary Figure S4. (A) A and T alleles frequencies in control 
group and in patients stratified intoparticular risk group. In SR group: 21 A alleles (58.3%) and 15 T 
alleles (41,7%); IR group: 35 Aalleles (56.5%) and 27 T alleles (43.5%); HR group: 8 A alleles (40%) 
and 12 T alleles (60%). (B) Comparison of percentage of individuals having at least one A allele to 
TT genotype, alike incontrols and in patient stratified into particular risk groups. In SR group: AA 
and AT genotype: 15patients (83.3%), TT genotype: 3 patients (16.7%); in IR group: AA and AT 
genotype: 26 patients (83.9%), TT genotype: 5 patients (16.1%); in HR group: AA and AT genotype: 
6 patients (60%), TT genotype: 4 patients (40%). (C) Comparison of percentage of individuals with 
AA genotype alike in controls and in patient stratified into particular risk groups. In SR group: AA 
genotype: 6 patients (33.3%), AT and TT genotype: 12 patients (66.6%); in IR group: AA genotype: 
9 patients (29%), ATand TT genotype: 22 patients (71%); in HR group: AA genotype: 2 patients (20%), 
AT and TT genotype: 8 patients (80%).
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